Mecbotamab vedotin
Based on 1 Customer Validation
Mecbotamab vedotin (BA3011) is a pH dependent antibody drug conjugate (ADC) targeting AXL. Mecbotamab vedotin can significantly inhibit AXL in DU145 cells and LCLC-103H cells and kills cells. Mecbotamab vedotin can be used for research on cancer such as lung cancer, pancreatic cancer and prostate cancer. The antibody component is Mecbotamab (HY-P9988), and the ADC toxin molecule is Monomethyl auristatin E (MMAE) (HY-15162).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.21%
- CAS No.: 2460400-64-8
-
보관:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
IC50 & Target
AXL; BA301 γ1[1]
In Vitro
Mecbotamab vedotin (0.1-10000 ng/mL) efficiently binds to AXL at pH 6.0 in DU145 cells (EC50 = 16 ng/mL), LCLC-103H cells (EC50 = 37 ng/mL), 293-huAXL (EC50 = 56 ng/mL) and 293-cynoAXL (EC50 = 20 ng/mL)[1].
Mecbotamab vedotin (0.01-10000 ng/mL, 3 days) exhibits significant cytotoxicity at pH 6.0 in DU145 cells (IC50 = 1466 ng/mL) and LCLC-103H cells (IC50 = 474 ng/mL) but is non-toxic to 293-F cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DU145 cells, LCLC-103H cells and 293-F cells
-
Concentration:0.01-10000 ng/mL
-
Incubation Time:3 days
-
Result:Significantly killed the DU145 cells (IC50 = 1466 ng/mL) and LCLC-103H cells (IC50 = 474 ng/mL) at pH 6.0.
Effectively killed the DU145 cells (IC50 = 5069 ng/mL) and LCLC-103H cells (IC50 = 1095 ng/mL) at pH 7.4.
Had no significant toxicity to 293-F cells.
In Vivo
Mecbotamab vedotin (1-10 mg/kg, i.v., once every 4 days, for 4 times) significantly inhibits tumor growth in female NOD/SCID mice bearing MIA PaCa-2 tumors[1].
Mecbotamab vedotin (6-15 mg/kg, i.v., once every 4 days, for 6 times) significantly delayed tumor growth in male BALB/c nude mice bearing DU145 tumors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:1×106 LCLC-103H cells injected female NOD/SCID mice[1]
-
Dosage:1, 3 and 6 mg/kg
-
Administration:Intravenous injection (i.v.), once every 4 days, for 6 times
-
Result:Significantly inhibited tumor growth (TGI range of 114-115%) and the efficacy of the 3 and 6 mg/kg groups persisted until 57 days.
-
Animal Model:1×106 MIA PaCa-2 cells injected female NOD/SCID mice[1]
-
Dosage:1, 3, 6 and 10 mg/kg
-
Administration:Intravenous injection (i.v.), once every 4 days, for 4 times
-
Result:Resulted in a TGI of 59% in the 6 mg/kg group and complete tumor regression in the 10 mg/kg group.
-
Animal Model:5×106 DU145 cells injected female NOD/SCID mice[1]
-
Dosage:6, 10 and 15 mg/kg
-
Administration:Intravenous injection (i.v.), once every 4 days, for 6 times
-
Result:Showed persistent anti-tumor activity in the 10 and 15 mg/kg groups.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2460400-64-8
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Mecbotamab vedotin]
-
Synonyms
BA3011; CAB-Axl-ADC; CAB-anti-Axl-ADC
-
선적
Shipping with dry ice.
-
보관
-80°C, protect from light
순도&문서
-
Data Sheet (270 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Mecbotamab vedotin Related Classifications
HY-145622 Related Classifications
Powered by Bioz